How do I interpret my genomic profiling results for Colorectal Cancer

Understanding Your Colorectal Cancer Genomic Profiling Results

Genomic profiling is a powerful tool that analyzes the genetic mutations in your cancer cells. These results help your oncology team understand your specific cancer and guide treatment decisions. Let me walk you through the key findings you might see.

THE MAIN BIOMARKERS YOUR DOCTOR WILL TEST

According to NCCN Guidelines for Colon Cancer, all patients with colorectal cancer should have testing for several important genetic markers:

1. RAS and BRAF Mutations (KRAS, NRAS, BRAF)

What it means: These genes control how cells grow and divide. When mutated, they can make cancer cells grow faster and affect how well certain treatments work.

How to interpret it:

• Wild-type (normal): Your cancer doesn't have these mutations—this is generally favorable for treatment options
• KRAS or NRAS mutation present: According to NCCN Guidelines, this means you should NOT receive cetuximab or panitumumab (EGFR inhibitors), which are antibody drugs that target a different pathway. However, there's an exception: if you have a specific KRAS G12C mutation, targeted therapy may still be an option
• BRAF V600E mutation: This is a more aggressive mutation. NCCN Guidelines note that response to EGFR inhibitors is "highly unlikely" unless combined with a BRAF inhibitor

Questions to ask your doctor:

1. Do I have any RAS or BRAF mutations, and what does this mean for my treatment options?
2. If I have a BRAF mutation, am I a candidate for BRAF inhibitor therapy?
3. Are there clinical trials available for my specific mutation?

---

2. MMR/MSI Status (Mismatch Repair & Microsatellite Instability)

What it means: These tests check whether your cancer cells can properly repair DNA mistakes. This is one of the most important tests for colorectal cancer.

How to interpret it:

• MMR-proficient or MSI-stable (pMMR/MSS): Your cells have normal DNA repair—this is the most common type (~95% of cases)
• MMR-deficient or MSI-high (dMMR/MSI-H): Your cells have broken DNA repair machinery (~3-5% of metastatic cases). According to NCCN Guidelines, this is actually GOOD NEWS because:
  • Your cancer has many mutations that the immune system can recognize
  • You may benefit from checkpoint inhibitor immunotherapy (drugs like pembrolizumab or nivolumab)
  • For stage II disease specifically, MSI-H tumors often have a better prognosis and may NOT need chemotherapy

Important note about Lynch Syndrome: If you have dMMR/MSI-H, NCCN Guidelines recommend testing for Lynch syndrome (a hereditary cancer condition). If you have MLH1 loss, your doctor should also test for BRAF mutations or MLH1 promoter methylation to determine if this is hereditary or sporadic.

Questions to ask your doctor:

1. What is my MMR/MSI status, and what does it mean for my prognosis?
2. If I have dMMR/MSI-H disease, am I eligible for immunotherapy?
3. Do I need genetic counseling to assess for Lynch syndrome?
4. If I have stage II disease with MSI-H, do I need chemotherapy?

---

3. HER2 Status

What it means: HER2 is a protein that can be overexpressed (too much) on cancer cells, making them grow faster.

How to interpret it:

• HER2 negative (0 or 1+): Standard treatment approaches apply
• HER2 2+: Needs additional testing (FISH) to confirm
• HER2 3+ or amplified by FISH: If you also have wild-type RAS and BRAF, you may be eligible for anti-HER2 therapy (like trastuzumab/pertuzumab combinations), according to NCCN Guidelines

Questions to ask your doctor:

1. What is my HER2 status?
2. If positive, am I a candidate for HER2-targeted therapy?
3. How does HER2 status affect my treatment plan?

---

4. POLE/POLD1 Mutations (Less Common)

What it means: These genes help proofread DNA during replication. Mutations cause many additional mutations to accumulate.

How to interpret it:

• POLE/POLD1 pathogenic mutation: Similar to MSI-H, this creates a "hypermutated" tumor that may respond to checkpoint inhibitor immunotherapy
• According to NCCN Guidelines, patients with POLE pathogenic mutations showed improved outcomes with PD-1/PD-L1 inhibitors

Questions to ask your doctor:

1. Do I have a POLE or POLD1 mutation?
2. If yes, am I eligible for immunotherapy?

---

5. NTRK Fusions (Extremely Rare)

What it means: NTRK fusions are found in less than 1% of colorectal cancers, mostly in MSI-H tumors.

How to interpret it:

• If present, NTRK inhibitors (like larotrectinib) may be an option
• NCCN Guidelines note that RNA-based sequencing is the most reliable way to detect these

---

UNDERSTANDING YOUR REPORT: WHAT TO LOOK FOR

When you receive your genomic report, look for:

1. Testing method used (NGS, IHC, FISH, etc.)—this tells you how reliable the results are
2. Each mutation listed individually with its status (present/absent, wild-type/mutant)
3. Confidence level or quality metrics
4. Recommendations from the lab about clinical implications

---

PROGNOSTIC TOOLS: ADDITIONAL TESTS

Your doctor may also order multigene assays to predict recurrence risk:

• Oncotype DX Colon Cancer: Analyzes 7 genes to classify risk as low, intermediate, or high
• ColoPrint: Uses 18 genes to predict recurrence risk
• Immunoscore: Measures immune cell density in your tumor

According to NCCN Guidelines, these tests provide prognostic information (predicting outcomes) but are NOT predictive of whether you'll benefit from specific treatments.

---

CIRCULATING TUMOR DNA (ctDNA) TESTING

Some patients receive blood-based tests that detect cancer DNA fragments:

• Post-surgery: Can identify patients at higher risk of recurrence
• During treatment: Can help monitor response
• According to NCCN Guidelines, ctDNA detection after surgery is associated with significantly higher recurrence risk

---

KEY QUESTIONS TO ASK YOUR ONCOLOGIST

1. "What are my specific mutations, and what do they mean for my treatment?"
2. "Based on my genomic profile, what treatment options are available to me?"
3. "Are there clinical trials I'm eligible for based on my mutations?"
4. "Do any of my results suggest I need genetic counseling?"
5. "Will my tumor be retested if my cancer progresses?" (NCCN Guidelines note that molecular profiles can change after targeted therapies)
6. "How do these results affect my prognosis and follow-up plan?"

---

IMPORTANT CONTEXT

According to NCCN Guidelines, genomic testing should be performed in CLIA-certified laboratories (Clinical Laboratory Improvement Amendments), which ensures quality and accuracy. Your results are most reliable when testing is done on tumor tissue, though blood-based testing is increasingly available.

Remember: Your genomic profile is one piece of the puzzle. Your oncologist will combine these results with your stage, overall health, and other factors to create your personalized treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.